SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) MAY 20, 1996
ENZON, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 0-12957 22-237286
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification)
20 KINGSBRIDGE ROAD, PISCATAWAY, NEW JERSEY 08854
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (908) 980-4500
(Former name or former address, if changed since last report)
<PAGE>
ITEM 5. OTHER EVENTS
Enzon, Inc. ("Enzon" or the "Company") completed its Phase Ia
clinical trial in healthy volunteers at the end of 1995, and received
approval from the FDA to enter a multi-dose trial in cancer patients.
Enrollment of patients for this trial has been unexpectedly slow, and as a
result, the Company has just opened a second site and plans to add
additional sites. The clinical supplies for the trial have been delivered
to the open sites. To expedite completion of this trial, a clinical
research organization will be utilized to accelerate patient recruitment,
monitor the study, and compile results.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated: May 29, 1996
ENZON, INC.
(Registrant)
By: /s/KENNETH J. ZUERBLIS
Kenneth J. Zuerblis
Vice President, Finance
and Chief Financial
Officer